These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27214874)

  • 1. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
    Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
    Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
    Orandi BJ; Zachary AA; Dagher NN; Bagnasco SM; Garonzik-Wang JM; Van Arendonk KJ; Gupta N; Lonze BE; Alachkar N; Kraus ES; Desai NM; Locke JE; Racusen LC; Segev DL; Montgomery RA
    Transplantation; 2014 Oct; 98(8):857-63. PubMed ID: 25121475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
    Montgomery RA; Orandi BJ; Racusen L; Jackson AM; Garonzik-Wang JM; Shah T; Woodle ES; Sommerer C; Fitts D; Rockich K; Zhang P; Uknis ME
    Am J Transplant; 2016 Dec; 16(12):3468-3478. PubMed ID: 27184779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
    Pinelli DF; Zachary AA; Friedewald JJ; Gjertson DW; Evans MA; Chatroop EN; Leffell MS; Vo AA; Jordan SC; Montgomery RA; Tambur AR
    Am J Transplant; 2019 Feb; 19(2):381-390. PubMed ID: 29981209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.
    De Sousa-Amorim E; Revuelta I; Blasco M; Diekmann F; Cid J; Lozano M; Sánchez-Escuredo A; Martorell J; Palou E; Campistol JM; Oppenheimer F
    Transplant Proc; 2015 Oct; 47(8):2332-5. PubMed ID: 26518919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
    Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
    Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
    Kimball PM; McDougan FA; King A
    Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With
    Zhu L; Guo Z; Sa R; Guo H; Li J; Chen G
    Front Immunol; 2021; 12():661614. PubMed ID: 33936098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants.
    Lee CY; Lin WC; Wu MS; Yang CY; Yeh CC; Tsai MK
    J Formos Med Assoc; 2016 Oct; 115(10):845-852. PubMed ID: 27542515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.